|
|
 Previous Article | Table of Contents | Next Article 
Correlation Between Mutation in P53, p53 Expression, Cytogenetics, Histologic Type, and Survival in Patients With B-Cell Non-Hodgkin's Lymphoma
Prasad R.K. Koduru,
Karthik Raju,
Veena Vadmal,
Geetha Menezes,
Shefali Shah,
Myron Susin,
Jonathan Kolitz, and
John D. Broome
From the Cell Genetics Laboratory, Department of Laboratories and Don Monti Division of Oncology-Division of Hematology, Department of Medicine, North Shore University Hospital, Manhasset, NY; and Department of Pathology and Medicine, New York University School of Medicine, New York, NY.
In the biology of a cell, the central role of p53 in controlling functions such as G1/S transition (check point) and DNA damage repair, and as a trigger of apoptosis, is well established. Somatic mutations or other changes in P53 have been reported in numerous tumor types, and in some of these, they are associated with poor prognosis. In this study, we examined 237 cytogenetically characterized B-cell non-Hodgkin's lymphomas (B-NHLs) for somatic changes in P53 by Southern blot analysis, by single-strand conformation polymorphism analysis (SSCP) of exon 5 through 9, and by direct sequencing of SSCP variants to determine the frequency and types of mutations and their clinical significance. In a portion of these (173 tumors), we also studied p53 expression by immunostaining. On Southern blots, no gross change was identified in P53 and no mutation was identified in exon 9. In exons 5 through 8, 27 different mutations were identified in 25 patients (23 single-base substitutions, 3 deletions, 1 duplication). Mutations in P53 were identified in 25 of 237 tumors (10.5%), which included 1 of 45 small lymphocytic lymphomas (SLLs), 2 of 38 follicular small cleaved-cell lymphomas (FSCCs), 2 of 35 follicular mixed small cleaved-cell and large-cell lymphomas (FMxs), 1 of 4 follicular large-cell lymphomas (FLCs), 1 of 14 diffuse small cleaved-cell lymphomas (DSCCs), 2 of 17 diffuse mixed small- and large-cell lymphomas (DMxs), and 16 of 84 diffuse large-cell lymphomas (DLCCs); the difference between the histologic groups was significant (P < .01). Among mantle-cell lymphoma (MC) patients, 3 of 10 had mutations. In 16 patients, the mutation was identified in specimens obtained at diagnosis. Mutation of transition type and transversion type occurred at a relative frequency of 2:1. Thirty percent occurred at CpG dinucleotide sequences and the codon for arginine was most frequently affected. Nineteen of 99 tumors with complex cytogenetic abnormalities, but none of 69 tumors with simple cytogenetic abnormalities, had mutations (P < .001). Similarly, 11 of 25 tumors with an abnormality of 17p and 8 of 143 tumors with apparently normal 17p had mutations (P < .0001). Positive correlations were found between a mutation and p53 expression (P < .001), between missense type mutations and p53 expression (P < .005), and between 17p abnormalities and p53 expression (P < .05). Twenty-two of 49 patients without mutation and 14 of 17 patients with mutations died (P < .05), but there was no significant difference in median survival. Similarly, 21 of 26 p53 positive patients died, whereas only 1 of 24 p53-negative patients died on-study (P < .001). Among p53-negative patients, mutation (P < .01) was positively associated with a fatal outcome. These findings indicate that in B-NHL, somatic changes in P53 were present in diagnostic specimens of all histologic types, but at a higher frequency in DLC and MC tumors. P53 mutation and/or expression has a negative influence on survival, and therefore can serve as prognostic indicators. Immunostaining for p53 is an effective way to screen for P53 changes in these tumors.
Blood, Vol. 90 No. 10 (November 15), 1997:
pp. 4078-4091
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Roue, M. Lopez-Guerra, P. Milpied, P. Perez-Galan, N. Villamor, E. Montserrat, E. Campo, and D. Colomer
Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling
Clin. Cancer Res.,
November 1, 2008;
14(21):
6907 - 6915.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. H. Young, K. Leroy, M. B. Moller, G. W. B. Colleoni, M. Sanchez-Beato, F. R. Kerbauy, C. Haioun, J. C. Eickhoff, A. H. Young, P. Gaulard, et al.
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study
Blood,
October 15, 2008;
112(8):
3088 - 3098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. O'Shea, C. O'Riain, C. Taylor, R. Waters, E. Carlotti, F. MacDougall, J. Gribben, A. Rosenwald, G. Ott, L. M. Rimsza, et al.
The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival
Blood,
October 15, 2008;
112(8):
3126 - 3129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Jardin, P. Ruminy, J.-P. Kerckaert, F. Parmentier, J.-M. Picquenot, S. Quief, C. Villenet, G. Buchonnet, M. Tosi, T. Frebourg, et al.
Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas
Haematologica,
April 1, 2008;
93(4):
543 - 550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. H. Young, D. D. Weisenburger, B. J. Dave, L. Smith, W. Sanger, J. Iqbal, E. Campo, J. Delabie, R. D. Gascoyne, G. Ott, et al.
Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma
Blood,
December 15, 2007;
110(13):
4396 - 4405.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Kaderali, T. Zander, U. Faigle, J. Wolf, J. L. Schultze, and R. Schrader
CASPAR: a hierarchical bayesian approach to predict survival times in cancer from gene expression data
Bioinformatics,
June 15, 2006;
22(12):
1495 - 1502.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Lossos
Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6351 - 6357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Lossos, D. K. Czerwinski, A. A. Alizadeh, M. A. Wechser, R. Tibshirani, D. Botstein, and R. Levy
Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six Genes
N. Engl. J. Med.,
April 29, 2004;
350(18):
1828 - 1837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sanchez-Beato, A. Sanchez-Aguilera, and M. A. Piris
Cell cycle deregulation in B-cell lymphomas
Blood,
February 15, 2003;
101(4):
1220 - 1235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Leroy, C. Haioun, E. Lepage, N. Le Metayer, F. Berger, E. Labouyrie, V. Meignin, B. Petit, C. Bastard, G. Salles, et al.
p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas
Ann. Onc.,
July 1, 2002;
13(7):
1108 - 1115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Achten, G. Verhoef, L. Vanuytsel, and C. De Wolf-Peeters
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Distinct Clinicopathologic Entity
J. Clin. Oncol.,
March 1, 2002;
20(5):
1269 - 1277.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E Matutes
New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders
J. Clin. Pathol.,
March 1, 2002;
55(3):
180 - 183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Barrans, I. Carter, R. G. Owen, F. E. Davies, R. D. Patmore, A. P. Haynes, G. J. Morgan, and A. S. Jack
Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma
Blood,
February 15, 2002;
99(4):
1136 - 1143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Lee, G. R. Petroni, C. A. Schiffer, C. E. Freter, J. L. Johnson, M. Barcos, G. Frizzera, C. D. Bloomfield, and B. A. Peterson
Brief-Duration High-Intensity Chemotherapy for Patients With Small Noncleaved-Cell Lymphoma or FAB L3 Acute Lymphocytic Leukemia: Results of Cancer and Leukemia Group B Study 9251
J. Clin. Oncol.,
October 15, 2001;
19(20):
4014 - 4022.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Lossos, C. D. Jones, R. Warnke, Y. Natkunam, H. Kaizer, J. L. Zehnder, R. Tibshirani, and R. Levy
Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma
Blood,
August 15, 2001;
98(4):
945 - 951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Gruszka-Westwood, R. A. Hamoudi, E. Matutes, E. Tuset, and D. Catovsky
p53 abnormalities in splenic lymphoma with villous lymphocytes
Blood,
June 1, 2001;
97(11):
3552 - 3558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Wiese, S. S. Gauny, W.-C. Liu, C. L. Cherbonnel-Lasserre, and A. Kronenberg
Different Mechanisms of Radiation-induced Loss of Heterozygosity in Two Human Lymphoid Cell Lines from a Single Donor
Cancer Res.,
February 1, 2001;
61(3):
1129 - 1137.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. Adida, C. Haioun, P. Gaulard, E. Lepage, P. Morel, J. Briere, H. Dombret, F. Reyes, J. Diebold, C. Gisselbrecht, et al.
Prognostic significance of survivin expression in diffuse large B-cell lymphomas
Blood,
September 1, 2000;
96(5):
1921 - 1925.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Corn, S. J. Kuerbitz, M. M. van Noesel, M. Esteller, N. Compitello, S. B. Baylin, and J. G. Herman
Transcriptional Silencing of the p73 Gene in Acute Lymphoblastic Leukemia and Burkitt's Lymphoma Is Associated with 5' CpG Island Methylation
Cancer Res.,
July 1, 1999;
59(14):
3352 - 3356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bea, M. Ribas, J. M. Hernandez, F. Bosch, M. Pinyol, L. Hernandez, J. L. Garcia, T. Flores, M. Gonzalez, A. Lopez-Guillermo, et al.
Increased Number of Chromosomal Imbalances and High-Level DNA Amplifications in Mantle Cell Lymphoma Are Associated With Blastoid Variants
Blood,
June 15, 1999;
93(12):
4365 - 4374.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Moller, A.-M. Gerdes, K. Skjodt, L. S. Mortensen, and N. T. Pedersen
Disrupted p53 Function as Predictor of Treatment Failure and Poor Prognosis in B- and T-Cell Non-Hodgkin's Lymphoma
Clin. Cancer Res.,
May 1, 1999;
5(5):
1085 - 1091.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
